Enhertu – pharmaceutical daily

February 3, 2025 Off

Roche gets FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

Roche announced Monday that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with ENHERTU®.

May 29, 2020 Off

AstraZeneca with promising results from clinics for Imfinzi and Enhertu

By Dino Mustafić

AstraZeneca on Friday reported several clinical results from its studies, including Imfinzi and Enhertu, with meaningful outcomes.

May 22, 2020 Off

Enhertu granted orphan drug designation in the US for gastric cancer

By Dino Mustafić

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.